laboratory specialized in the treatment of rare neurological diseases

« A disruptive technology, which can be applied in the treatment of numerous conditions »

> Documents

> Documents

2022

IRIS 13 January 2022 equity line summary (discontinued)
Télécharger le PDF (133 Ko)

IRIS 18 January 2021 equity line summary (discontinued)
Télécharger le PDF (520 Ko)

2021

Investor deck (27/09/2021)
Download PDF file (1120 Ko)

2020 annual results Portzamparc investor deck (08/04/2021)
Download PDF file (520 Ko)

Biomed conference investor deck (26/01/2021)
Download PDF file (520 Ko)

2020

CF&B Investor Conference April 2020

14/04/2020
Download PDF File (2,1Mo)

Presentation of the results of the phase 2 study of THN102 in Parkinson’s disease

31/03/2020
Download PDF File (2,1Mo)

Presentation of THN201 P1b results

15/01/2020
Dowload PDF File (825 Ko)

Investor presentation January 2020

28/01/2020
Download PDF File (3,2Mo)

2019

Investor Presentation
27/06/2019
Download PDF File (1,2 Mo)

2018

Investor Presentation - Biotech Agora april 10th 2018 (in French)
10/04/2018
Download PDF file (2,09 Mo)

Reference Document registered under n°R.18-028 (in French)
27/04/2018
Download PDF file (10,4 Mo)

Investor presentation - Portzamparc conference april 4th 2018 (in French)
04/04/2018
Download PDF file (2,43 Mo)

2017

Biomed event - December 2017
19/12/2017
Download PDF File (2,79 Mo)
Investors presentation - October 2017
12/10/2017
Download PDF File (2,79 Mo)
Securities note (French only)
11/10/2017
Download PDF File (1,88 Mo)
Base document n°I.17-068 (french only)
27/09/2017
Download PDF File (8,5 Mo)